Ghost Tree Capital »

Inhibrx shares owned by Ghost Tree Capital

Quarter-by-quarter ownership of Inhibrx (INBX) shares owned by Ghost Tree Capital from 13F filings

Historical chart of Ghost Tree Capital investment in Inhibrx

Tip: Access up to 7 years of quarterly data

All positions including Inhibrx held by Ghost Tree Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibrx by Ghost Tree Capital

Quarter filed Position value Share count Share price at filing
2023-09-30 $642k 35k 18.35
2023-06-30 $909k 35k 25.96

More positions owned by Ghost Tree Capital

Moonlake Immunotherapeutics Class A Ord (MLTX)
Sarepta Therapeutics (SRPT)
Spdr Ser Tr S&p Biotech Call Option (XBI)
Akero Therapeutics (AKRO)
Krystal Biotech (KRYS)
Madrigal Pharmaceuticals (MDGL)
Tg Therapeutics (TGTX)
Immunovant (IMVT)
Ascendis Pharma A/s Sponsored Adr (ASND)
Axsome Therapeutics (AXSM)
Alpine Immune Sciences (ALPN)
Syndax Pharmaceuticals (SNDX)
Vaxcyte (PCVX)
Tarsus Pharmaceuticals (TARS)
Apellis Pharmaceuticals Call Option (APLS)

View all positions for Ghost Tree Capital

Top funds holding Inhibrx

Viking Global Investors
RA Capital Management
Perceptive Advisors
Vanguard Group
Arrowpoint Asset Management
Bank of America Corporation
Logos Global Management
Partner Fund Management
Russell Investments
Citadel Advisors
Caption Management
Millennium Management
Charles Schwab Investment Management
Sphera Funds Management
Two Sigma Advisers

View all funds holding Inhibrx